清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Identification of MDM4 as a Prognostic Biomarker and a Target for Therapeutics in Colorectal Cancer

结直肠癌 免疫疗法 微卫星不稳定性 免疫系统 医学 生物标志物 癌变 平方毫米 肿瘤微环境 疾病 癌症 免疫检查点 癌症研究 肿瘤科 免疫学 生物信息学 内科学 生物 基因 等位基因 生物化学 微卫星
作者
Xiao Shang,Xiaoqiang Zheng,Aimin Jiang,Ni Zhao,Yuru Chen,Na Liu,Min Chen,Xuan Liang,Zhiping Ruan,Tao Tian,Xiao Fu,Yu Yao
出处
期刊:Biotechnology and Applied Biochemistry [Wiley]
卷期号:73 (1): 28-42 被引量:1
标识
DOI:10.1002/bab.70002
摘要

Colorectal cancer (CRC) is a serious global health problem. Even with improvements in CRC diagnosis and treatment, many patients are diagnosed with metastatic disease, indicating the tumor has metastasized, and the survival rate for those with advanced CRC is still low. Immune checkpoint inhibitors (ICIs) have shown some promise for certain groups of CRC patients, specifically for those with mismatch repair deficiencies or microsatellite instability, but their overall effectiveness is still limited. Novel biomarkers and treatment targets are critically needed for the improvement of the diagnosis and treatment of CRC, ultimately improving patient outcomes. MDM4 (murine double minute 4) protein is important in controlling the tumor suppressor p53. MDM4 is similar in structure to MDM2 and is known to block p53's transcriptional ability, which can contribute to tumorigenesis. MDM4 is often found at higher levels in many cancers, including CRC, and has been linked to cancer progression through mechanisms that don't involve p53. However, MDM4's role in the tumor immune microenvironment of CRC remains unclear; its role in CRC prognosis and response to immunotherapy isn't fully understood. This study explores the biological, clinical, and immunological impact of MDM4 in CRC, focusing on its potential as a marker for prognosis and treatment target. This study is the first to comprehensively link MDM4 overexpression in CRC to immune evasion through reduced infiltration of CD8+ T cells and dendritic cells, establishing its role as an independent prognostic marker and a potential immunotherapy target. We explored the role of MDM4 in CRC by combining bioinformatic analyses and laboratory experiments. We gathered data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databasesWe performed Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, and Gene Set Enrichment Analysis (GSEA) to identify the key biological pathways linked to MDM4 in CRC. We also explored how MDM4 expression is associated with the immune microenvironment by examining the tumor-infiltrating lymphocytes in CRC tissues. Laboratory experiments were conducted to test the functional role of MDM4 in CRC cell lines. Our analysis showed that MDM4 expression was higher in CRC than in normal colorectal tissues, with even higher levels found in more advanced tumor stages. Increased MDM4 expression was linked to poorer progression-free survival (PFS) in CRC patients and was identified as an independent predictor of prognosis. Through pathway enrichment analyses, we found that MDM4 was involved in important tumor-related and immune pathways, including those regulating cell cycle progression and immune response. Notably, overexpression of MDM4 was associated with lower infiltration of CD8 T cells, natural killer (NK) cells, and dendritic cells in the tumor microenvironment, suggesting that MDM4 might help the tumor evade the immune system. In vitro experiments further confirmed these findings, showing that reducing MDM4 expression significantly slowed CRC cell growth and induced apoptosis. These results highlight the tumor-promoting role of MDM4 in CRC and suggest its possibility of becoming a therapeutic target. MDM4 is important in the progression and immune evasion of CRC. Its increased expression is implicated in disease progression and worse clinical outcomes, making it a valuable independent prognostic marker for CRC. Furthermore, MDM4's involvement in immune regulation, particularly in decreasing immune cell infiltration, suggests its potential as a target for immunotherapy. Targeting MDM4 could provide a new CRC treatment strategy, potentially improving patient outcomes by inhibiting tumor growth and boosting immune responses. Further research is needed to confirm MDM4 as a therapeutic target and to gain a deeper understanding of its function in CRC immunotherapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
17991完成签到,获得积分10
2秒前
苗苗完成签到,获得积分10
10秒前
vbnn完成签到 ,获得积分10
19秒前
20秒前
忘忧Aquarius完成签到,获得积分0
21秒前
buqi完成签到,获得积分10
22秒前
25秒前
linj完成签到,获得积分10
26秒前
petrichor完成签到 ,获得积分10
26秒前
正常糖完成签到 ,获得积分10
31秒前
独特问梅完成签到,获得积分10
33秒前
单纯冰菱完成签到,获得积分10
37秒前
小蘑菇的应助被TingtingGZ采纳,获得10
39秒前
berry完成签到,获得积分10
47秒前
Jasonkun完成签到,获得积分10
48秒前
jlin完成签到,获得积分10
50秒前
creep2020完成签到,获得积分0
58秒前
muriel完成签到,获得积分0
1分钟前
冷静的尔竹完成签到,获得积分10
1分钟前
无奈小玉完成签到,获得积分10
1分钟前
1分钟前
CodeCraft的应助被蜗牛好好飞采纳,获得10
1分钟前
珈沐完成签到,获得积分10
1分钟前
TingtingGZ发布了新的文献求助10
1分钟前
e746700020完成签到,获得积分10
1分钟前
火星上的小蚂蚁完成签到,获得积分10
1分钟前
耍酷平凡完成签到,获得积分10
1分钟前
mailang完成签到,获得积分10
1分钟前
1分钟前
体贴雪萍完成签到,获得积分10
1分钟前
房天川完成签到 ,获得积分10
1分钟前
明朗完成签到 ,获得积分0
1分钟前
1分钟前
lynn发布了新的文献求助10
1分钟前
1分钟前
lynn完成签到,获得积分20
1分钟前
正直寻绿完成签到,获得积分10
1分钟前
cocolinfly完成签到 ,获得积分10
2分钟前
科目三的应助被TingtingGZ采纳,获得10
2分钟前
多情莫言完成签到,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173213
求助须知:如何正确求助?哪些是违规求助? 9565567
关于积分的说明 21780511
捐赠科研通 7767373
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555730
邀请新用户注册赠送积分活动 2476697